Review
Lapatinib ditosylate GlaxoSmithKline
Affiliations
- PMID: 12964069
Item in Clipboard
Review
Lapatinib ditosylate GlaxoSmithKline
IDrugs.
2003 Sep.
Abstract
Lapatinib ditosylate, an ErbB-2 and EGFR dual tyrosine kinase inhibitor, is being developed by GlaxoSmithKline plc for the potential treatment of solid tumors.
Similar articles
-
BAY-43-9006 Bayer/Onyx.Curr Opin Investig Drugs. 2003 Jun;4(6):757-63. Curr Opin Investig Drugs. 2003. PMID: 12901237 Review.
-
BMS-247550 Bristol-Myers Squibb/GBF.Curr Opin Investig Drugs. 2003 Jun;4(6):746-56. Curr Opin Investig Drugs. 2003. PMID: 12901236 Review.
-
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Clin Ther. 2008. PMID: 18803986 Review.
-
109881 Aventis.Curr Opin Investig Drugs. 2003 Jun;4(6):737-40. Curr Opin Investig Drugs. 2003. PMID: 12901234 Review.
-
Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.Ann Pharmacother. 2006 Feb;40(2):261-9. doi: 10.1345/aph.1G387. Epub 2006 Jan 17. Ann Pharmacother. 2006. PMID: 16418322 Review.
Cited by
-
Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.Nat Chem Biol. 2013 Nov;9(11):677-84. doi: 10.1038/nchembio.1335. Epub 2013 Sep 1. Nat Chem Biol. 2013. PMID: 23995768 Free PMC article.
-
HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression.Springerplus. 2013 Aug 15;2:386. doi: 10.1186/2193-1801-2-386. eCollection 2013. Springerplus. 2013. PMID: 24102037 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous